Annals of Oncology Advance Access originally published online on February 13, 2007
Annals of Oncology 2007 18(5):945-949; doi:10.1093/annonc/mdl499
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
palliative care |
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Department of Surgery, Nottingham University Hospitals, Nottingham City Hospital Campus, Nottingham, UK
* Correspondence to: Dr A. A. Ayantunde, Department of Surgery, Nottingham University Hospitals, Nottingham City Hospital Campus, Nottingham, NG5 1PB, UK. Tel: +44-115-969-1169; Fax: +44-115-962-7764; E-mail: biodunayantunde{at}yahoo.co.uk
Background: Malignant ascites is a manifestation of end stage events in a variety of cancers and associated with a poor prognosis. We evaluated the pattern of cancers causing malignant ascites and factors affecting survival.
Patients and methods: Patients coded with the International Classification of Diseases-9 coding system for malignant ascites over a 2-year period were reviewed. The clinicopathological data and patients' survival were compared among cancer groups.
Results: There were 209 patients (140 females and 69 males), median age being 67 (30–98) years. The commonest cancer was ovarian followed by gastrointestinal (GI) cancers. Fifty-eight per cent of the patients had symptoms related to the ascites. Liver metastases were significantly commoner in the GI cancers (P = 0.0001). Fifty-four per cent of our patients presented with ascites at the initial diagnosis of their cancer. Paracentesis was given to 112, diuretics to 70 and chemotherapy to 103 patients. The median survival following diagnosis of ascites was 5.7 months. Ovarian cancer favoured longer survival while low serum albumin, low serum protein and liver metastases adversely affected survival. The independent prognostic factors for survival were cancer type, liver metastases and serum albumin.
Conclusion: The identified independent prognostic factors should be used to select patients for multimodality therapy for adequate palliation.
Key words: cancers, chemotherapy, malignant ascites, paracentesis, prognotic factors, survival
Received for publication August 10, 2006. Revision received November 3, 2006. Revision received December 11, 2006. Accepted for publication December 15, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. M. Moss, M. V. Barbolina, Y. Liu, L. Sun, H. G. Munshi, and M. S. Stack Ovarian Cancer Cell Detachment and Multicellular Aggregate Formation Are Regulated by Membrane Type 1 Matrix Metalloproteinase: A Potential Role in I.p. Metastatic Dissemination Cancer Res., September 1, 2009; 69(17): 7121 - 7129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, X. Jiang, M. Zhang, H. Xu, G. Zhai, and B. Li The Role of 18F-FDG PET/CT in the Evaluation of Ascites of Undetermined Origin J. Nucl. Med., April 1, 2009; 50(4): 506 - 512. [Abstract] [Full Text] [PDF]
|
|